Biomea Fusion's (BMEA) Buy Rating Reaffirmed at HC Wainwright
Biomea Fusion's (BMEA) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Biomea Fusion (NASDAQ:BMEA – Get Rating) in a report published on Friday morning. They currently have a $37.00 target price on the stock. HC Wainwright also issued estimates for Biomea Fusion's FY2024 earnings at ($2.53) EPS, FY2025 earnings at ($2.68) EPS and FY2026 earnings at ($2.28) EPS.
HC Wainwright在周五上午发布的一份报告中重申了他们对Biomea Fusion(纳斯达克：BMEA-GET评级)股票的买入评级。他们目前对该股的目标价为37.00美元。HC Wainwright还发布了对Biomea Fusion 2024财年每股收益(2.53美元)、2025财年每股收益(2.68美元)和2026财年每股收益(2.28美元)的预期。
Separately, EF Hutton Acquisition Co. I reduced their target price on Biomea Fusion from $27.00 to $22.00 and set a buy rating on the stock in a research report on Tuesday, November 8th.
另外，EF Hutton Acquisition Co.I在11月8日周二的一份研究报告中将Biomea Fusion的目标价从27.00美元下调至22.00美元，并对该股设定了买入评级。
Biomea Fusion Price Performance
Biomea融合性价比
Shares of NASDAQ:BMEA opened at $7.91 on Friday. The business's 50-day moving average is $8.41 and its 200 day moving average is $10.01. Biomea Fusion has a 1 year low of $2.84 and a 1 year high of $14.20. The firm has a market capitalization of $232.52 million, a P/E ratio of -3.24 and a beta of -1.80.
纳斯达克：非洲、中东和非洲股票上周五开盘报7.91美元。该业务的50日移动均线切入位在8.41美元，200日移动均线切入位在10.01美元。Biomea Fusion的一年低点为2.84美元，一年高位为14.20美元。该公司的市值为2.3252亿美元，市盈率为-3.24，贝塔系数为-1.80。
Insider Buying and Selling at Biomea Fusion
Biomea Fusion的内部买入和卖出
Institutional Investors Weigh In On Biomea Fusion
机构投资者参与Biomea Fusion
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Biomea Fusion by 2.0% during the first quarter. BlackRock Inc. now owns 1,705,442 shares of the company's stock worth $7,606,000 after buying an additional 32,634 shares during the period. Vanguard Group Inc. boosted its holdings in Biomea Fusion by 18.5% in the third quarter. Vanguard Group Inc. now owns 803,118 shares of the company's stock valued at $7,854,000 after purchasing an additional 125,311 shares during the period. Laurion Capital Management LP boosted its holdings in Biomea Fusion by 2.2% in the third quarter. Laurion Capital Management LP now owns 429,400 shares of the company's stock valued at $4,200,000 after purchasing an additional 9,251 shares during the period. Citadel Advisors LLC boosted its holdings in Biomea Fusion by 540.5% in the second quarter. Citadel Advisors LLC now owns 335,191 shares of the company's stock valued at $4,016,000 after purchasing an additional 282,855 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Biomea Fusion by 1,475.9% in the second quarter. JPMorgan Chase & Co. now owns 273,925 shares of the company's stock valued at $3,281,000 after purchasing an additional 256,543 shares during the period. Institutional investors and hedge funds own 58.19% of the company's stock.
对冲基金和其他机构投资者最近改变了他们在该股的头寸。贝莱德股份有限公司在第一季度将其在Biomea Fusion的股票持仓量增加了2.0%。贝莱德股份有限公司在此期间增持了32,634股，目前持有1,705,442股该公司股票，价值7,606,000美元。先锋集团(Vanguard Group Inc.)在第三季度增持了Biomea Fusion 18.5%的股份。先锋集团目前持有803,118股该公司股票，价值7,854,000美元，在此期间又购买了125,311股。Laurion Capital Management LP在第三季度增持了2.2%的Biomea Fusion。Laurion Capital Management LP现在拥有该公司429,400股股票，价值4,200,000美元，在此期间又购买了9,251股。Citadel Advisors LLC在第二季度将其在Biomea Fusion的持股增加了540.5%。Citadel Advisors LLC在此期间额外购买了282,855股，目前拥有335,191股该公司股票，价值4,016,000美元。最后，摩根大通在第二季度将其在Biomea Fusion的持股增加了1,475.9%。摩根大通在此期间增持了256,543股，目前持有273,925股该公司股票，价值3,281,000美元。机构投资者和对冲基金持有该公司58.19%的股票。
Biomea Fusion Company Profile
Biomea Fusion公司简介
(Get Rating)
(获取评级)
Biomea Fusion, Inc, a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
Biomea Fusion，Inc.是一家生物制药公司，专注于发现和开发共价小分子药物，用于治疗基因定义的癌症和代谢性疾病患者。它的主要候选产品是BMF-219，一种口服生物可用、有效和选择性的薄荷素共价抑制剂，它是多种癌症致癌信号中的转录调节因子。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Biomea Fusion (BMEA)
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
- Four Profitable RV Stocks To Ride Out Recession
- 免费获取StockNews.com关于Biomea Fusion(BMEA)的研究报告
- 2023年值得关注的5个下跌但不是下跌的股票
- Chewy能否在2023年获得两位数的增长？
- 礼来公司预计将实现持久增长，尽管面临眼前的挑战
- Madrigal制药公司的股票在一天内上涨了200%，原因如下
- 四只盈利的房车股安然度过经济衰退
Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.
接受Biomea Fusion Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Biomea Fusion和相关公司的最新新闻和分析师评级的每日简明摘要。